Review

July 1, 2024


Current status and perspective on molecular targets and therapeutic intervention strategy in hepatic ischemia-reperfusion injury
Jia Liu, Ranyi Luo, Yinhao Zhang, et al.
Clin Mol Hepatol. 2024;30(4):585-619.

Review

July 11, 2024


Immunological mechanisms in steatotic liver diseases: An overview and clinical perspectives
Mengyao Yan, Shuli Man, Long Ma, et al.
Clin Mol Hepatol. 2024;30(4):620-648.

Original Article

May 29, 2024


Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting
Xueshuai Wan, Karin Wisskirchen, Tao Jin, et al.
Clin Mol Hepatol. 2024;30(4):735-755.

Original Article

June 24, 2024


Burden of mortality from hepatocellular carcinoma and biliary tract cancers by race and ethnicity and sex in US, 2018–2023
Donghee Kim, Richie Manikat, Karn Wijarnpreecha, et al.
Clin Mol Hepatol. 2024;30(4):756-770.

Original Article

June 25, 2024


UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL
Renyu Zhang, Can Li, Shuai Zhang, et al.
Clin Mol Hepatol. 2024;30(4):771-792.

Original Article

July 19, 2024


Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B
Gi-Ae Kim, Seung Won Choi, Seungbong Han, et al.
Clin Mol Hepatol. 2024;30(4):793-806.

Original Article

July 23, 2024


Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial
Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, et al.
Clin Mol Hepatol. 2024;30(4):807-823.

Original Article

July 25, 2024


DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease
Amal Magdy, Hee-Jin Kim, Hanyong Go, et al.
Clin Mol Hepatol. 2024;30(4):824-844.

Original Article

July 25, 2024


Gut microbiome and metabolome signatures in liver cirrhosis-related complications
Satya Priya Sharma, Haripriya Gupta, Goo-Hyun Kwon, et al.
Clin Mol Hepatol. 2024;30(4):845-862.

Original Article

July 26, 2024


TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD
Baokai Sun, Xiaoqian Ding, Jie Tan, et al.
Clin Mol Hepatol. 2024;30(4):863-882.

Original Article

July 29, 2024


Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan
Chung-Feng Huang, Chia-Yen Dai, Yi-Hung Lin, et al.
Clin Mol Hepatol. 2024;30(4):883-894.

Original Article

August 5, 2024


KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression
Young Hoon Jung, Yun Ji Lee, Tam Dao, et al.
Clin Mol Hepatol. 2024;30(4):895-913.

Original Article

August 6, 2024


Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma
Yu-Hang Ye, Hao-Yang Xin, Jia-Li Li, et al.
Clin Mol Hepatol. 2024;30(4):914-928.

Original Article

August 27, 2024


The prognostic impact of psychiatric intervention on alcohol-associated liver disease: The UK Biobank cohort study
Keungmo Yang, Sunghwan Kim, Hyun Yang, et al.
Clin Mol Hepatol. 2024;30(4):929-942.

Original Article

August 29, 2024


Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: A multinational population-based cohort study from South Korea, Japan, and the UK
Kwanjoo Lee, Jaeyu Park, Jinseok Lee, et al.
Clin Mol Hepatol. 2024;30(4):943-958.


Review
1955
Current status and perspective on molecular targets and therapeutic intervention strategy in hepatic ischemia-reperfusion injury
Jia Liu, Ranyi Luo, Yinhao Zhang, Xiaojiaoyang Li
Clin Mol Hepatol. 2024;30(4):585-619.   Published online July 1, 2024
View: 1586   Download: 221
1967
Immunological mechanisms in steatotic liver diseases: An overview and clinical perspectives
Mengyao Yan, Shuli Man, Long Ma, Lanping Guo, Luqi Huang, Wenyuan Gao
Clin Mol Hepatol. 2024;30(4):620-648.   Published online July 11, 2024
View: 1386   Download: 158
Original Article
1940
Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting
Xueshuai Wan, Karin Wisskirchen, Tao Jin, Lu Yang, Xiaorui Wang, Xiang’an Wu, Fang Liu, Yu Wu, Christy Ma, Yong Pang, Qi Li, Ke Zhang, Ulrike Protzer, Shunda Du
Clin Mol Hepatol. 2024;30(4):735-755.   Published online May 29, 2024
View: 1473   Download: 190  Crossref: 2
1951
Burden of mortality from hepatocellular carcinoma and biliary tract cancers by race and ethnicity and sex in US, 2018–2023
Donghee Kim, Richie Manikat, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
Clin Mol Hepatol. 2024;30(4):756-770.   Published online June 24, 2024
View: 1266   Download: 65
1952
UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL
Renyu Zhang, Can Li, Shuai Zhang, Lingmin Kong, Zekun Liu, Yixiao Guo, Ying Sun, Cong Zhang, Yule Yong, Jianjun Lv, Meng Lu, Man Liu, Dong Wu, Tianjiao Zhang, Haijiao Yang, Ding Wei, Zhinan Chen, Huijie Bian
Clin Mol Hepatol. 2024;30(4):771-792.   Published online June 25, 2024
View: 1217   Download: 235
1972
Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B
Gi-Ae Kim, Seung Won Choi, Seungbong Han, Young-Suk Lim
Clin Mol Hepatol. 2024;30(4):793-806.   Published online July 19, 2024
View: 1399   Download: 145  Crossref: 1
1975
Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial
Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, Bohwa Sohn, Yun Seong Jeong, Sang-Hee Kang, Kena Park, Hyewon Park, Sunyoung S. Lee, Ahmed O. Kaseb, Young Nyun Park, Sun-Hee Leem, Michael A. Curran, Ji Hoon Kim, Ju-Seog Lee
Clin Mol Hepatol. 2024;30(4):807-823.   Published online July 23, 2024
View: 1508   Download: 221  Crossref: 2
1982
DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease
Amal Magdy, Hee-Jin Kim, Hanyong Go, Jun Min Lee, Hyun Ahm Sohn, Keeok Haam, Hyo-Jung Jung, Jong-Lyul Park, Taekyeong Yoo, Eun-Soo Kwon, Dong Hyeon Lee, Murim Choi, Keon Wook Kang, Won Kim, Mirang Kim, on behalf of the Innovative Target Exploration of NAFLD (ITEN) Consortium
Clin Mol Hepatol. 2024;30(4):824-844.   Published online July 25, 2024
View: 1192   Download: 233
1984
Gut microbiome and metabolome signatures in liver cirrhosis-related complications
Satya Priya Sharma, Haripriya Gupta, Goo-Hyun Kwon, Sang Yoon Lee, Seol Hee Song, Jeoung Su Kim, Jeong Ha Park, Min Ju Kim, Dong-Hoon Yang, Hyunjoon Park, Sung-Min Won, Jin-Ju Jeong, Ki-Kwang Oh, Jung A Eom, Kyeong Jin Lee, Sang Jun Yoon, Young Lim Ham, Gwang Ho Baik, Dong Joon Kim, Ki Tae Suk
Clin Mol Hepatol. 2024;30(4):845-862.   Published online July 25, 2024
View: 3153   Download: 911  Crossref: 1
1985
TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD
Baokai Sun, Xiaoqian Ding, Jie Tan, Jie Zhang, Xueru Chu, Shuimi Zhang, Shousheng Liu, Zhenzhen Zhao, Shiying Xuan, Yongning Xin, Likun Zhuang
Clin Mol Hepatol. 2024;30(4):863-882.   Published online July 26, 2024
View: 1035   Download: 183
1990
Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan
Chung-Feng Huang, Chia-Yen Dai, Yi-Hung Lin, Chih-Wen Wang, Tyng-Yuan Jang, Po-Cheng Liang, Tzu-Chun Lin, Pei-Chien Tsai, Yu-Ju Wei, Ming-Lun Yeh, Ming-Yen Hsieh, Chao-Kuan Huang, Jee-Fu Huang, Wan-Long Chuang, Ming-Lung Yu
Clin Mol Hepatol. 2024;30(4):883-894.   Published online July 29, 2024
View: 728   Download: 73
1992
KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression
Young Hoon Jung, Yun Ji Lee, Tam Dao, Kyung Hee Jung, Junjie Yu, Ah-Reum Oh, Yelin Jeong, HyunJoon Gi, Young Un Kim, Dongryeol Ryu, Michele Carrer, Utpal B. Pajvani, Sang Bae Lee, Soon-Sun Hong, KyeongJin Kim
Clin Mol Hepatol. 2024;30(4):895-913.   Published online August 5, 2024
View: 1228   Download: 230
2001
Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma
Yu-Hang Ye, Hao-Yang Xin, Jia-Li Li, Ning Li, Si-Yuan Pan, Long Chen, Jing-Yue Pan, Zhi-Qiang Hu, Peng-Cheng Wang, Chu-Bin Luo, Rong-Qi Sun, Jia Fan, Jian Zhou, Zheng-Jun Zhou, Shao-Lai Zhou
Clin Mol Hepatol. 2024;30(4):914-928.   Published online August 6, 2024
View: 924   Download: 142  Crossref: 1
2020
The prognostic impact of psychiatric intervention on alcohol-associated liver disease: The UK Biobank cohort study
Keungmo Yang, Sunghwan Kim, Hyun Yang, Sheng-Min Wang, Bumseok Jeong, Hyun Kook Lim, Si Hyun Bae
Clin Mol Hepatol. 2024;30(4):929-942.   Published online August 27, 2024
View: 768   Download: 90
2024
Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: A multinational population-based cohort study from South Korea, Japan, and the UK
Kwanjoo Lee, Jaeyu Park, Jinseok Lee, Myeongcheol Lee, Hyeon Jin Kim, Yejun Son, Sang Youl Rhee, Lee Smith, Masoud Rahmati, Jiseung Kang, Hayeon Lee, Yeonjung Ha, Dong Keon Yon
Clin Mol Hepatol. 2024;30(4):943-958.   Published online August 29, 2024
View: 1029   Download: 92  Crossref: 2
Letter to the Editor
1929
Changing from NAFLD to MASLD: Cumulative incidence of gallstones between patients with NAFLD and those with MASLD in Asia
Shuhei Fukunaga, Tomoyuki Nakane, Michita Mukasa, Hidetoshi Takedatsu, Takumi Kawaguchi
Clin Mol Hepatol. 2024;30(4):959-961.   Published online May 10, 2024
View: 941   Download: 53  Crossref: 2
1935
Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi
Clin Mol Hepatol. 2024;30(4):962-964.   Published online May 20, 2024
View: 971   Download: 88  Crossref: 3
Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality
Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
Clin Mol Hepatol. 2024;30(4):982-986.   Published online August 27, 2024
View: 559   Download: 36
Correspondence
Correspondence to editorial on “Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets”
Yingzhou Shi, Guandou Yuan, Xiude Fan, Chao Xu
Clin Mol Hepatol. 2024;30(4):987-988.   Published online April 19, 2024
View: 902   Download: 27
Correspondence to editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”
Chang Hun Lee, In Hee Kim, Sook-Hyang Jeong
Clin Mol Hepatol. 2024;30(4):997-999.   Published online July 29, 2024
View: 474   Download: 22
Correspondence to editorial on “Liver sinusoidal endothelial cell: An important yet often overlooked player in the liver fibrosis”
Jiaorong Qu, Le Wang, Xiaojiaoyang Li
Clin Mol Hepatol. 2024;30(4):1002-1004.   Published online May 17, 2024
View: 843   Download: 40
Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”
Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim
Clin Mol Hepatol. 2024;30(4):1005-1008.   Published online May 30, 2024
View: 923   Download: 39
Correspondence to editorial on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma”
Chun-Ting Ho, Elise Chia-Hui Tan, Chien-Wei Su
Clin Mol Hepatol. 2024;30(4):1016-1018.   Published online May 20, 2024
View: 805   Download: 26
Correspondence to editorial on “Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy”
Qi Wang, Qingfa Bu, Haoming Zhou, Ling Lu
Clin Mol Hepatol. 2024;30(4):1026-1027.   Published online July 8, 2024
View: 577   Download: 36
Correspondence on editorial regarding “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”
Mehrangiz Dezhbord, Kyun-Hwan Kim
Clin Mol Hepatol. 2024;30(4):1028-1030.   Published online July 9, 2024
View: 985   Download: 70  Crossref: 1
Reply to Correspondence
Reply to correspondence on “Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide”
Pin-Nan Cheng, Ming-Lung Yu
Clin Mol Hepatol. 2024;30(4):1031-1032.   Published online April 11, 2024
View: 976   Download: 35
Reply to correspondence on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study”
Eileen Laurel Yoon, Dae Won Jun
Clin Mol Hepatol. 2024;30(4):1033-1034.   Published online May 20, 2024
View: 728   Download: 17
Reply to correspondence on “Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets”
Mohammad Saeid Rezaee-Zavareh, Naomy Kim, Ju Dong Yang
Clin Mol Hepatol. 2024;30(4):1037-1038.   Published online May 2, 2024
View: 930   Download: 47
Reply to correspondence on “Severity of microvascular invasion does matter in hepatocellular carcinoma prognosis”
Abdelrahman M Attia, Hasmik Adetyan, Ju Dong Yang
Clin Mol Hepatol. 2024;30(4):1042-1043.   Published online August 27, 2024
View: 423   Download: 20  Crossref: 1
Reply to correspondence on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”
Seren M. Gedallovich, Paul Y. Kwo
Clin Mol Hepatol. 2024;30(4):1050-1052.   Published online July 12, 2024
View: 617   Download: 20
Reply to correspondence on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”
Cho-Rong Lee, Sung-Gyoo Park
Clin Mol Hepatol. 2024;30(4):1053-1054.   Published online July 17, 2024
View: 962   Download: 31  Crossref: 1
Snapshot
1901
Examining the therapeutic landscape of beta-blockers in portal hypertension
Anna Brujats, Càndid Villanueva
Clin Mol Hepatol. 2024;30(4):1055-1059.   Published online March 6, 2024
View: 5473   Download: 49
Erratum
1981
Erratum to ‘Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction’ [Clin Mol Hepatol 2024;30:539-560]
Mehrangiz Dezhbord, Seong Ho Kim, Soree Park, Da Rae Lee, Nayeon Kim, Juhee Won, Ah Ram Lee, Dong-Sik Kim, Kyun-Hwan Kim
Clin Mol Hepatol. 2024;30(4):1060-1065.   Published online July 24, 2024
View: 688   Download: 20

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

  • PubMed Central
  • PubMed
  • Scopus
  • KoreaMed
  • KoMCI
  • ScienceCentral
  • DOAJ
  • GoogleScholar
  • Similarity Check
  • Crossref Cited-by Linking
  • CrossMark
  • Funder Registry
  • Metadata
  • ORCID
  • MeSH on Demand
  • COPE
  • EMBASE
  • KOFST
  • ICMJE
  • Web of SCIENCE
Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: cmh_journal@ijpnc.com
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 476
TOTAL : 2158221
Close layer